<DOC>
	<DOCNO>NCT02508207</DOCNO>
	<brief_summary>To evaluate clinical mechanism action lung extrapulmonary system VX-661 combination ivacaftor ( IVA ) ( VX-661/IVA ) subject cystic fibrosis ( CF ) homozygous F508del mutation CF transmembrane conductance regulator ( CFTR ) gene .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Effects VX-661/Ivacaftor Lung Extrapulmonary Systems Subjects With Cystic Fibrosis , Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female subject Homozygous F508del CFTR mutation Confirmed diagnosis CF sweat chloride test FEV1 ≥40 % ≤90 % predict normal age , sex , height Screening Visit Stable CF disease judge investigator . History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject . An acute upper low respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 28 day Day 1 History evidence clinically significant finding ophthalmologic examination Screening Period . History solid organ hematological transplantation Pregnant nursing female Subjects radiation exposure within 1 year first MCC procedure would cause exceed federal regulation participate study In opinion investigator , unable adequately perform inhalation maneuver MCC procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>